The Economic Times

Weight is over! Pharma stocks jump up to 4% as patent for Ozempic's key ingredient expires; what lies ahead?

Pharma stocks rose up to 4% as Novo Nordisks semaglutide patent nears expiry, raising expectations of cheaper generics in India. Strong growth potential in GLP-1 drugs, low penetration, and aggressive pricing by domestic players like Natco Pharma are driving investor interest in the sector.